ESMO 2023: The Impact of New Data on Patient Care

Rana R. McKay, MD

November 13, 2023

Rana R. McKay, MD, reviews updates in prostate cancer care that were presented at ESMO 2023 — notably, the PSMAfore trial, which revealed significant improvements in progression-free survival, prostate-specific antigen responses, and objective responses with ¹⁷⁷Lu-PSMA-617 therapy. The data suggest a potential use for ¹⁷⁷Lu-PSMA-617 in the pre-chemotherapy setting for certain patients.

Additionally, the EMBARK study showed that enzalutamide in combination with leuprolide did not compromise quality of life for patients with non-metastatic, biochemically recurrent prostate cancer. Dr McKay also discusses the use of artificial intelligence through the Artera MMAI platform, which proved valuable for prognostic assessment, aiding in treatment decision-making. Together, Dr McKay concludes that these findings will inform day-to-day clinical practice.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ESMO 2023: The Impact of New Data on Patient Care - Medscape - Nov 13, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.